Fuse Medical, Inc.

The company's financials show resilient growth, with revenue advancing from $4.54M in Q3 2022 to $5.00M in Q2 2023. Gross profit remained healthy with margins at 69% in Q2 2023 compared to 67% in Q3 2022. Operating income hit $368859.00 last quarter, sustaining a consistent 7% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $401574.00. Net income rose to $307588.00, while earnings per share reached $0.004. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.